Slides
Page 1
IR PRESENTATION June 2025
Page 2
SAFE HARBOR STATEMENT Forward-looking statements involve risks. This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements. 2
Page 3
Leading OEM player for automation solutions for the diagnostics industry and translational research Three decades of experience in highly regulated healthcare markets and growing technology pool Around 1.500 employees worldwide Around 50% allocable to R&D Production sites in Germany (HQ), Switzerland, Hungary, Austria and in the United States High number of systems installed globally More than 50,000 systems Sales of € 257.6 million in 2024 CAGR sales since IPO in 1998: ~13% Sales split 2024: Systems 32% Service parts and consumables 43% Development and services 25% STRATEC AT A GLANCE SELECTED PRODUCTS 3
Page 4
UNIQUE POSITION WITHIN THEVALUE CHAIN 4 Partner Market Access Reagents Plastic Consumables Software Analyzer Systems STRATEC provides instrumentation, consumables, software and automation solutions OEM development and manufacturing Several thousand automated analyzer systems manufactured annual ly Wide range of intellectual property rights / broad technology pool Long market lifecycles lead to longstanding partnerships Product lifecycles for a system typically in an area of 12 to 15 years Expanding installed base of systems Product enhancement and extension drives value / Life cycle management Development and market launch of successor product 2 to 4 years development phase Another 5 years of service parts & consumables 12 to 15 years Marketing phase of the analyzer system Service part & consumables Indicative revenue characteristics of an analyzer OEM project Long-term contractual setup Milestone payments during development stage (linked to agreed development budget and development targets) Operating sales during series production stage - minimum volume commitment by partner, firm transfer price) Recurring sales from service parts & consumables strong commitment by both partners Shared responsibilities
Page 5
ACTIVE IN FAST GROWING SEGMENTS 5 IVD MARKET SEGMENTS / IVD MARKET: ~100 BILLION USD IVD market by technologies IVD market by product group Molecular Diagnostics Random access analyser systems (mid-to-high throughput) Smart consumables (multiplexing) POC devices (multiplexing) with smart consumables Focus on market segments with above average complexity and growth Immunoassay Random access analyzer systems (mid-to-high throughput) Classic plastic consumables Smart consumables Hematology & other routine testing Decentralized testing solutions Veterinary diagnostics Plastics Further specialities / focus areas Immunohematology Complex Sample Processing Tissue Diagnostics Translational Research Source: MarketsandMarkets Research; own estimates
Page 6
BENEFITTING FROM OUTSOURCING TREND 6 OUTSOURCED VS IN HOUSE INSTRUMENTATION MARKET Proportion of outsourced instrumentation developments over time The majority of instrumentation equipment in the IVD market is still developed in-house by diagnostics companies. Share of outsourced developments has already increased significantly over the last couple of years. Past Ongoing paradigm shift even within the „blue chips“ towards outsourcing Trend of outsourcing towards specialized players set to continue, due to: Engineering of automation solutions often not core competence of diagnostics companies Shorter development timeframes due to already existent technology pools Guaranteed project budget and firm transfer prices Keeping up with regulatory developments easier for specialized players Structured processes in order to address end customer needs, such as ease of use, user experience, workflow efficiencies, remote access, serviceability and preventive maintenance
Page 7
STRONG RECURRING REVENUE BASE 7 Service parts and consumables (43% of sales) Maintenance parts Spare parts Classic plastic consumables (eg. Pipetting tips, reaction vessels) Smart consumables (highly complex cartridges; microfluidics, molding, mastering and coating technologies) Fueled by growing installed base and increasing complexity Continuously growing number of active systems in the lab Strong upward trend in the average complexity of systems Sales split 2024 Installed base 1 1 Estimated with the assumption of an average six year replacement cycle in the lab SIMOA TM 24-ASSAY DISC Quanterix VITEK ® MS Disposable target slide bioMérieux Smart consumables Classic consumables Stackable Cuvette STRATEC Perestaltic Pump STRATEC Service and spare parts Installed base (number of system) Systems 32% Development and Services 25% Service Parts and Consumables 43% 12,000 22,000 32,000 42,000 52,000 62,000 2019 2020 2021 2022 2023 2024
Page 8
STRONG LONG-TERM CUSTOMER RELATIONSHIPS 8 A SELECTION OF STRATEC CUSTOMERS Source: IVD News / non-public companies estimated / non-reported sector sales estimated STRATEC customer Not a STRATEC customer … And other technology pioneers GLOBAL TOP 20 IVD COMPANIES Sales 2024 (USD billion) 1. Roche 16.9 2. Danaher 9.9 3. Abbott 9.3 4. Siemens 4.8 5. Thermo Fisher 4.5 6. Becton Dickinson 3.7 7. bioMerieux 3.7 8. Sysmex 3.1 9. Exact Sciences 2.8 10. QuidelOrtho 2.8 11. Illumina 2.4 12. CH Werfen ( Inova, IL, Biokit) 2.3 13. Shenzhen Mindray 1.9 14. Hologic 1.8 15. Natera 1.7 16. Agilent Tech 1.7 17. Bio-Rad 1.5 18. Revvity (formerly PerkinElmer) 1.5 19. DiaSorin 1.3 20. Diagnostica Stago 1.0
Page 9
HIGH-SENSITIVITY IMMUNOASSAYS MARKET – FOCUS AREAS 9 EXPAND DOMINANT MARKET POSITION WITH INNOVATORS AND ESTABLISHED PLAYERS Neurological applications Proteomics Research Market: $2.0bn Source: Customer information Focus Areas: • High-Multiplexing up to full proteome • Single Molecule Detection T echnologies • High-Throughput rare-biomarker screening (Neuro-Degenerative Diseases) How STRATEC can capitalize: • Dominant market position and established trustful partnerships with leading players • Comprehensive offering through combined pool of instrument and consumable technologies Market trends: • Transfer of single molecule technologies into the clinical labs • Breakthrough discoveries in neurodegenerative diseases triggers demand for diagnostic assays and therapy monitoring solutions
Page 10
ADVANCED IMAGING MARKET – FOCUS AREAS 10 DYNAMIC MARKET WITH EXPECTED PUSH BY AI 0.8 1.1 0.9 1.8 2.5 3.1 2.3 2.8 0 1 2 3 4 5 6 7 8 9 10 2023 2027 High content Imaging Digital Pathology Flow Cytrometry Microscopy 6.5 8.8 $bn CAGR ~8% ~5% ~6% ~19% ~8% T otal addressable tools market – Advanced Imaging 1 1 Excluding in-vitro diagnostics Source: DeciBio, own estimates Focus Areas: • Automation for digital imaging allowing for the combination of traditional H&E stains with custom fluorescence labels • Sample prep workflows allowing for flexibility to add different sample types and quality How STRATEC can capitalize: • Use of the common modules and proven reliability of their interplay allowing for highly cost effective systems • Flexible hardware & software architecture to ensure interoperability and long-term system sustainability • Strong software team including data-scientists to exploit AI enabled workflows at a rapid pace Market trends: • High-Content, High Resolution imaging providing powerful datasets for both clinical research and prognostic healthcare
Page 11
CELL & GENE THERAPY MARKET – FOCUS AREAS 11 FAST -GROWING MARKET WITH UNMET NEED FOR AUTOMATION 0.3 0.7 0.5 1.1 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 2023 2027 Cell Isolation Generic Manipulation 0.8 1.8 $bn CAGR ~22% ~22% ~24% T otal addressable tools market – Cell Therapy Source: DeciBio, own estimates Focus Areas: • Cell Isolation (sorting and isolation of cell types of interest) • Transfection (genetic engineering of cells to create the therapy) How STRATEC can capitalize: • Significant need for automation across the entire workflow to lower cost per treatment and improve access • Need for high-throughput platforms for gene transfer, cell sorting, and cell expansion • Decentralization of the workflow: Providing safety and efficacy Market trends: • Increasing prevalence of complex and chronic diseases • Transformation of traditional blood-products / blood-banking applications to cell & gene therapy • New research expands market into new large indications (e.g. autoimmune disorders)
Page 12
FINANCIALS 12 FINANCIALS FY 2024 AT A GLANCE 1 bps = basis points cc = at constant currency 1 For comparison purposes, adjusted figures have been adjusted to exclude amortization from purchase price allocations in the context of acquisitions, as well as for other one-off items (consulting and reorganization expenses in connection with M&A activities and one-off personnel expenses). 2 Restated in accordance with IAS 8. € 000s FY 2024 FY 2023 2 Change Sales 257,624 270,414 -4.7 % (cc: -4.9%) Adjusted EBITDA 49,214 44,826 +9.8% Adjusted EBITDA margin (%) 19.1 16.6 +250 bps Adjusted EBIT 33,459 30,388 +10.1% Adjusted EBIT margin (%) 13.0 11.2 +180 bps Adjusted consolidated net income 20,496 19,009 +7.8% Adjusted basic earnings per share (in €) 1.69 1.56 +8.3% Basic earnings per share IFRS (in €) 1.32 1.26 +4.8%
Page 13
FINANCIALS 13 IMPACT DUE TO ADJUSTMENT OF ACCOUNTING METHOD Reported € 000s FY 2024 FY 2023 Sales 257,624 270,414 Adjusted EBIT 33,459 30,388 Adjusted EBIT margin (%) 13.0 11.2 Delta FY 2024 FY 2023 +18 +8,503 +966 +3,317 +40 bps +90 bps Before adjustment FY 2024 FY 2023 257,606 261,911 32,493 27,071 12.6 10.3 Guidance FY 2024 Stable to slight decline at cc 10.0 – 12.0 Targets achieved with beat on margin Joint analysis with new auditor results in upward adjustments bps = basis points, cc = at constant currency Based on a joint analysis with the new auditor, STRATEC made adjustments in accordance with IAS 8 (Accounting Policies, Changes in Accounting Estimates and Errors) to certain accounting methods. This particularly concerns the recognition of sales of development cooperations in accordance with IFRS 15 and the capitalization of intangible assets pursuant to IAS 38.
Page 14
FINANCIALS 14 SALES FY 2024 Sales in € million As of December 31 214.2 250.1 287.3 274.6 270.4 257.6 0 30 60 90 120 150 180 210 240 270 300 2019 2020 2021 2022 2023 2024 FY 2024 sales -4.9% yoy in constant currency to € 257.6 million • Pandemic related demand disruptions • Elevated inventory levels of customers at the beginning of the year • Flatter than expected ramp-up curve of products newly launched onto the market • Resilient growth with Service Parts and Consumables • Increased recognition of Development and Service sales
Page 15
FINANCIALS 15 SALES BY OPERATING DIVISIONS FY 2024 0 20 40 60 80 100 120 140 160 Systems Service Parts & Consumables Development and Services Others 2023 2024 +14.8% (+14.8% at cc) +9.8% (+9.2% at cc) -41.2% (-41.4% at cc) Sales in € million 21% 25% 36% 43% 42% 32% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2023 2024 Others Development and Services Service Parts & Consumables Systems In % of total sales As of December 31 cc= at constant currency -27.8% (-27.8% at cc)
Page 16
FINANCIALS 16 ADJUSTED EBIT AND EBIT MARGIN FY 2024 EBIT EBIT margin EBIT in € million EBIT margin in % As of December 31 29.3 41.7 54.3 45.1 30.4 33.5 13.7% 16.7% 18.9% 16.4% 11.2% 13.0% 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% 20% 22% 24% 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 2019 2020 2021 2022 2023 2024 FY 2024 adj. EBIT at € +10.1% to 33.5 million € Margin improvement of 180 bps Y oY to 13.0% • Strong gross margin development Gross margin up 440 bps Y oY to 29.7% Efficiency measures and structural changes taking effect Recognition of high margin sales related to development projects, licensing agreements, and services • FX • Still improvement potential for product mix within systems business • Negative economies of scale and increased functional costs € 000s FY 2024 FY 2023 Research and development expenses -11,612 -8,740 Sales-related expenses -12,456 -11,952 General administrative expenses -24,445 -19,255
Page 17
FINANCIALS 17 CASH FLOW AND NET DEBT • Strong cash flow dynamics due to increased profitability and decrease in trade receivables • Strong focus to reduce still elevated inventory levels going forward • Investment ratio 1 at 7.1% of sales and in line with projected corridor of 6.0% to 8.0% • Net debt / adj. EBITDA at 1.8x (down from 2.5x at the end of FY 2023) • Negotiations on refinancing of existing bridge loan by a new syndicated loan is ongoing (closing expected in July) € 000s FY 2024 FY 2023 Change Cash flow – operating activities 48,712 19,323 +152,1% Cash flow – investment activities -15,970 -44,054 n/a Cash flow – financing activities -20,301 35,442 n/a Free cash flow 32,742 -24,731 n/a € 000s FY 2024 FY 2023 Change Cash at end of period 47,164 33,532 +40,7% Equity ratio (%) 54.5 52.6 +190 bps Net debt 87,096 111,802 -22.1% 1 Total investments in intangible and tangible assets in % of sales € 000s FY 2024 FY 2023 Inventories 121,818 117,522 Trade receivables 41,578 58,059
Page 18
FINANCIALS 18 FINANCIALS Q1/2025 AT A GLANCE 1 bps = basis points cc = at constant currency 1 To facilitate comparison, figures have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses). 2 Restated in accordance with IAS 8. € 000s Q1/2025 Q1/2025 2 Change Sales 60,363 53,888 +12.0% (cc: +10.9%) Adjusted EBITDA 9,305 6,592 +41.2% Adjusted EBITDA margin (%) 15.4 12.2 +320 bps Adjusted EBIT 5,363 2,921 +83.6% Adjusted EBIT margin (%) 8.9 5.4 +350 bps Adjusted consolidated net income 3,155 1,064 +196.5% Adjusted basic earnings per share (in €) 0.26 0.09 +188.9% Basic earnings per share IFRS (in €) 0.12 0.02 +500.0%
Page 19
OUTLOOK Consolidated sales for the 2025 financial year expected to grow in a low to medium single-digit percentage range on a constant-currency basis 19 FINANCIAL GUIDANCE FOR FISCAL YEAR 2025 Adjusted EBIT margin of 10.0% to 12.0% (FY 2024: 13.0%) Earnings contributions from higher-margin development and services sales expected to be lower in FY 2025 Investments in tangible and intangible assets combined of around 8.0% to 10.0% of sales (FY 2024: 7.1%) Higher investments for development projects and IT
Page 20
Maintaining cost discipline throughout the company given earnings improvement measures implemented Continue to grow footprint in selected market focus areas (High- Sensitivity Immunoassays, Advanced Imaging, Cell & Gene Therapy) Manage and process well filled M&A pipeline according to external growth and diversification strategy Execute deal pipeline regarding new development and manufacturing agreements Continue l everaging the combined customer base of both, STRATEC and Natech OUTLOOK 20 FOCUS IN 2025 AND BEYOND Improve cash flow dynamics with strong focus on inventory efficiency
Page 21
CORPORATE SOCIAL RESPONSIBILITY 21 CORPORATE GOVERNANCE AS A BASIS FOR TRUST AND TRANSPARENCY Compliance management system in place to assure compliance with all national/international legislation ESG Board in place to identify and manage risks/opportunities related to sustainability. Climate targets 1 validated by the Science Based T argets initiative (SBTi) and thus consistency with the target set by the Paris Agreement of limiting global warming to 1.5°C. 1 Short-term targets: Reduction of absolute greenhouse gas emissions in Scope 1, 2 and 3 by 50,4% by 2032 compared with the 2023 base year | Long-term targets: Reduction of absolute greenhouse gas emissions in Scope 1, 2 and 3 by 90% by 2045 compared with the 2023 base year | Net zero targets: STRATEC is committed to achieving net zero greenhouse gas emissions throughout its value chain by 2045 SOCIAL RESPONSIBILITY TOWARDS PEOPLE AND SOCIETY Strong policies and measures to promote an open, tolerant and discrimination-free corporate culture Extensive occupational health/safety policies and programs Formulated goals for diversity and health/safety KPI’s with corresponding monitoring ECOLOGICAL RESPONSIBILITY FOR A BETTER TOMORROW Global Environmental Policy outlines the guiding principles and minimum standards of our environmental strategy. Developed transition plan that outlines the strategic measures and steps required to achieve our climate goals Signatory to the UN Global Compact of the United Nations STRATEC reduced its total Scope 1 and 2 emissions by 36% since 2019
Page 22
22
Page 23
APPENDIX 23 ADJUSTMENTS FY2024 Consolidated net income EBIT € 000s FY 2024 FY 2023 Adjusted EBIT 33,459 30,388 Adjustments: PPA amortization -3,679 -3,188 Other 1 -2,238 -1,496 EBIT 27,542 25,704 € 000s FY 2024 FY 2023 Adjusted consolidated net income 20,496 19,009 Adjusted earnings per share in € (basic) 1.69 1.56 Adjustments: PPA amortization -3,679 -3,188 Other 1 -2,238 -1,496 Taxes 1,442 1,045 Consolidated net income 16,021 15,370 Earnings per share in € (basic) 1.32 1.26 1 Advisory expenses and restructuring costs in connection with M& A activities as well as one-off personnel expenses 1 Advisory expenses and restructuring costs in connection with M& A activities as well as one-off personnel expenses
Page 24
APPENDIX 24 ADJUSTMENTS Q1/2025 Consolidated net income EBITDA € 000s Q1/2025 Q1/2024 1 Adjusted EBITDA 9,305 6,592 Adjustments: Other 2 -1,369 -48 EBITDA 7,936 6,544 € 000s Q1/2025 Q1/2024 1 Adjusted consolidated net income 3,155 1,064 Adjusted earnings per share in € (basic) 0.26 0.09 Adjustments: PPA amortization -924 -947 Other 2 -1,369 -48 Taxes 584 216 Consolidated net income 1,446 285 Earnings per share in € (basic) 0.12 0.02 1 Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report. 2 Including one-off advisory expenses, fees, and restructuring e xpenses EBIT € 000s Q1/2025 Q1/2024 1 Adjusted EBIT 5,363 2,921 Adjustments: PPA amortization -924 -947 Other 2 -1,369 -48 EBIT 3,070 1,926 1 Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report. 2 Including one-off advisory expenses, fees, and restructuring e xpenses
Page 25
APPENDIX KEY FIGURES AT A GLANCE 1 1 For comparison purposes, adjusted figures have been adjusted to exclude amortization from purchase price allocations in the context of acquisitions, as well as for other one-off items (consulting and reorganization expenses in connection with M&A activities and one-off personnel expenses). 2 Restated in accordance with IAS 8. 2 3 Subject to approval by the Annual General Meeting on June 27, 2025. IFRS (€ million) 2020 2021 2022 2023 2 2024 Sales 250.1 287.3 274.6 270.4 257.6 Adjusted EBIT 41.7 54.3 45.1 30.4 33.5 Adjusted EBIT margin (%) 16.7 18.9 16.4 11.2 13.0 Adjusted consolidated net income 35.2 45.1 34.7 19.0 20.5 Adjusted earnings per share (€) 2.92 3.73 2.86 1.56 1.69 Dividend per share (€) 0.90 0.95 0.97 0.55 0.60 3 No. of employees 1,319 1,398 1,481 1,522 1,450 Total assets 331.9 368.5 397.5 450.7 455.0 Equity ratio (%) 52.0 55.8 56.6 52.6 54.5 Free cash flow 10.0 43.3 -8.7 -24.7 33.7 25
Page 26
APPENDIX SHAREHOLDER STRUCTURE (AS OF: MAY 2025) SHARE IPO Aug. 1998 Number of shares 12,157,841 Share price (06/02/2025) € 27.30 Market capitalization € 332 million Institutional investors > 3%: • Brown Capital Management • JPMorgan Chase & Co. • Juno Investment Partners • Union Investment Privatfonds 26
Page 27
STRATEC SE Gewerbestr. 37 75217 Birkenfeld Germany Phone +49 7082 7916-0 Fax +49 7082 7916-999 www.stratec.com CONTACT THANK YOU FOR YOUR ATTENTION CONTACT Jan Keppeler, CFA Head of Investor Relations, Sustainability & Corporate Communications Phone +49 7082 7916-6515 j.keppeler@stratec.com 27